Literature DB >> 12954066

In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.

Kyle P Kokko1, M Kyle Hadden, Kevin S Orwig, Jean Mazella, Thomas A Dix.   

Abstract

A set of neurotensin[8-13] (NT[8-13]) analogues featuring substitution of non-natural cationic amino acids in the Arg(8) position have been synthesized and tested for binding potencies against the three cloned human NT receptors (hNTR-1, hNTR-2, hNTR-3), functional agonism of the hNTR1 and for rat serum stability. Three distinct classes of peptides have been identified: Class 1 features alkyl-Arg analogues at Arg(8), Class 2 features alpha-azido-cationic amino acids at Arg(8), and Class 3 feature modified Arg(8) and Tyr(11) residues. Most of the peptides maintain or exceed the binding potency of NT[8-13] to hNTR-1. Class 2 analogues exceed the binding potency of NT[8-13] to hNTR-2 with KK19 binding with higher affinity to hNTR-2 than hNTR-1. Peptides with enhanced binding potencies for hNTR-3 were not found. All analogues are functional agonists of the hNTR1 receptor as indicated by phosphoinositide (PI) determination. Serum stability increased with peptide classification where the half-life of Class 1 < Class 2 < Class 3 which are stable to rat serum for > 24 h.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954066     DOI: 10.1021/jm0300633

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic.

Authors:  Francis M Hughes; Brooke E Shaner; Lisa A May; Lyndsay Zotian; Justin O Brower; R Jeremy Woods; Michael Cash; Dustin Morrow; Fabienne Massa; Jean Mazella; Thomas A Dix
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 3.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

4.  Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

5.  Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin.

Authors:  Liuyin Zhang; Hee-Kyoung Lee; Timothy H Pruess; H Steve White; Grzegorz Bulaj
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446

6.  Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies.

Authors:  Simon Gonzalez; Maria Dumitrascuta; Emilie Eiselt; Stevany Louis; Linda Kunze; Annalisa Blasiol; Mélanie Vivancos; Santo Previti; Elke Dewolf; Charlotte Martin; Dirk Tourwé; Florine Cavelier; Louis Gendron; Philippe Sarret; Mariana Spetea; Steven Ballet
Journal:  J Med Chem       Date:  2020-09-23       Impact factor: 7.446

7.  Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors.

Authors:  Lisa Schindler; Jutta Moosbauer; Daniel Schmidt; Thilo Spruss; Lukas Grätz; Steffen Lüdeke; Frank Hofheinz; Sebastian Meister; Bernd Echtenacher; Günther Bernhardt; Jens Pietzsch; Dirk Hellwig; Max Keller
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

Review 8.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.